Project Grant 2415711
Award Date
8/15/24
Completion Date
7/31/25
Dollars Obligated
$275K
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
Camp Pendleton North, CA 92054, USA
Similar Awards
This National Science Foundation (NSF) SBIR Phase I award to Foragr Medicines, Inc. provides $275,000 to develop a high-throughput platform for small molecule targeting of undruggable proteins via their mRNAs. The project aims to create an efficient and cost-effective approach to discover new therapeutics for previously untreatable diseases, including neurodegenerative conditions and aggressive cancers. Key innovations include automating ligand screening against mRNA targets and enabling...
This $275,000 Small Business Innovation Research (SBIR) Phase I grant, awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program, aims to develop new bacterial hosts for the productive secretion of difficult-to-express proteins. The project, led by Wild Microbes Co, a for-profit organization in Cambridge, MA, seeks to engineer improved bacterial strains that can manufacture proteins found in detergents, personal care products, and...
The National Science Foundation (NSF) awarded a $274,438 SBIR Phase I grant to Script Biosciences Inc. under the NSF Technology, Innovation, and Partnerships (CFDA 47.084) program. The project, titled "CASPLUS: A Safer, More Efficient, and Targeted Method of Deploying CRISPR In Vivo," aims to develop a platform technology that significantly reduces the potential inaccuracy of current gene editing techniques. The innovation targets the desired gene, increasing the safety and efficacy of...
This award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $303,864 to Core Biotherapeutics Inc., a for-profit organization, to develop a platform for designing disruptive drug candidates that can address high unmet medical needs. The project aims to determine the biological laws governing molecular networks that drive diseases and program these into an efficient, scalable algorithm for drug target discovery. This...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) award of $274,947 to Lattice Therapeutics Inc. supports the development of a customizable, next-generation RNA delivery particle. The project aims to validate the ability of an engineerable protein nanoparticle platform to efficiently and specifically deliver RNA cargoes to target cancer cells. Key objectives include in vitro evaluation of RNA...
This Project Grant award from the National Science Foundation (NSF) under its Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 to Tectaria Bio LLC to engineer cell lines with activated proteasomes for increased biomanufacturing efficiency. The project aims to test the feasibility and application of a novel technology to significantly increase the protein production capabilities of cell lines used in the manufacture of biologics, gene therapies, and vaccines....
The National Science Foundation (NSF) awarded Pearl Bio, Inc., a biotechnology company, a $274,462 Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084). The grant funded the development of a next-generation biomanufacturing platform to engineer new microbial organisms and cellular machinery. This platform enables the incorporation of diverse, non-native components into proteins, creating a new class of biological materials for therapeutic development,...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $273,550 to Biocognon LLC, a small business in Pittsburgh, PA, aims to develop a novel yeast-based high-throughput screening platform for generating improved molecular recognition components for use in therapeutic and diagnostic antibodies. The 12-month project will demonstrate the platform's ability to efficiently produce molecular recognition domains that specifically...
This SBIR Phase I Project Grant awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $275,000 in funding to Terraferma Foods, Inc., a woman-owned small business located in San Francisco, CA. The project aims to develop a novel platform for accelerating the strain development process for precision fermentation, with the broader goal of reducing the environmental impact of livestock farming. Key products and...
This $274,991 Phase I Small Business Innovation Research (SBIR) award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a new approach to deliver cancer-killing proteins specifically to acute myeloid leukemia (AML) cells while sparing healthy cells. The project aims to engineer natural killer (NK) cells with targeted protein degraders (TPDs) against three common AML driver proteins, with the goal of demonstrating...